Merck Serono, the biopharmaceutical division of pharmaceutical conglomerate Merck, has made an investment in the series A round for US-based reproductive health company Auxogyn through its corporate venturing fund, Merck Serono Ventures. The round closed on Thursday, with Auxogyn having raised $20m.
Merck was joined in the round by TPG Biotech, the life sciences investment division of investment firm TPG, as well as venture capital firm Kleiner Perkins Caufield & Byers (KPCB).
Auxogyn’s lead product is Eeva, a non-invasive…
